Diagnosis, staging and treatment of patients with prostate cancer

Objectives

The National Clinical Guideline establishes an evidence-based national framework for diagnosing, staging and treating adults with newly diagnosed or metastatic prostate cancer in Ireland. It aims to improve care quality, consistency, safety, cost-effectiveness, survival and quality of life; reduce unwarranted variation; support effective interventions; and discourage ineffective practice across the patient journey.[1][2][3]

• Provide risk-stratified care using low-, intermediate-, high- and very-high-risk categories, informed by prostate-specific antigen, Gleason score and tumour stage.[4][5]
• Standardise diagnosis and staging through clinical examination, biopsy, pathology, multiparametric magnetic resonance imaging, computed tomography, isotope bone scanning and single-photon emission computed tomography where indicated.[6][7][8][9][10]
• Standardise pathology reporting for biopsy and radical prostatectomy specimens, including site-specific Gleason scores, tumour extent, prognostic factors, margin status and extraprostatic extension.[11][12][13][14]
• Offer active surveillance to appropriately selected men at lowest risk of progression who would otherwise be suitable for radical treatment, while using repeat biopsy, magnetic resonance imaging and clinical follow-up to identify progression.[15][16][17]
• Match radical prostatectomy, lymph-node dissection, radiotherapy, brachytherapy, hormone therapy, systemic treatments and salvage treatment to disease risk, recurrence status, symptoms, life expectancy and patient preferences.[18][19][20][21][22][23]
• Integrate palliative care early, assess needs continuously through illness, and ensure access to the level of palliative-care expertise appropriate to each patient’s needs.[24][25][26]
• Advance evidence-based practice through recommendations based on research evidence, clinical expertise and applicability to the Irish population and health-system context.[27][28]

Implementation

Implementation centres on multidisciplinary, clinically governed delivery in designated cancer services, supported by National Cancer Control Programme leadership, hospital accountability, implementation tools, audit and periodic evidence review. The National Cancer Control Programme commissioned and funded the guideline, while its recommendations were developed independently through structured evidence assessment and stakeholder review.[29][30][27][28]

• Deliver care through multidisciplinary teams involving relevant diagnostic, surgical, medical oncology, radiation oncology, pathology and palliative-care disciplines, and discuss every patient diagnosed with prostate cancer at a multidisciplinary team meeting.[31][2][32]
• Assign corporate responsibility for implementation to hospital chief executive officers, general managers and clinical directors, while requiring each multidisciplinary team member to implement recommendations relevant to their discipline.[29][30][4]
• Nominate a prostate cancer lead clinician in each prostate unit within designated cancer centres and agree annual prostate-care priorities for submission to the Health Service Executive Service Plan.[30]
• Use the Capability, Opportunity, Motivation-Behaviour model to identify implementation barriers and facilitators, then apply education, training, enablement and environmental restructuring as appropriate.[33][34]
• Support delivery through clinical governance across primary and secondary care, general practitioner referral guidance and electronic referrals, survivorship support, patient information, chemotherapy protocols and infection-prevention policy.[3][35][32]
• Develop recommendations through structured clinical questions, systematic searches, critical appraisal, considered judgement, evidence grading, service-user testing, national stakeholder review and international expert review.[27][28][36][37][38]
• Manage conflicts of interest through signed declarations and independent guideline development; a multidisciplinary Steering Group and Guideline Development Group provide governance and technical expertise.[29][39][40][41]
• Monitor implementation and patient outcomes through audit, establish key performance indicators through the Prostate National Clinical Lead's Network, and hold annual multidisciplinary Cancer Quality and Audit Fora.[29][30][32]
• Use quarterly meetings between the National Cancer Control Programme Cancer Network Manager and each cancer centre for performance monitoring and service planning.[30]
• Apply stated service standards, including rapid-access prostate-clinic appointments within 20 working days, biopsy histology reports within 10 working days in 80% of cases, radical-treatment commencement within 15 working days of readiness, and first surgery within 30 working days of the decision to treat.[32]
• Review the literature periodically and consider the guideline for review three years after publication, with interim and full updates subject to National Clinical Effectiveness Committee approval.[30]
• Assess resource implications for recommendations requiring practice change and seek additional resources through the Health Service Executive service-planning process where needed; many recommendations reflect current standard practice and are considered cost neutral.[30]

Monitoring & Evaluation

Implementation oversight combines national guideline governance, local corporate responsibility and clinical quality assurance. The National Clinical Effectiveness Committee periodically reports on guideline implementation and impact, National Clinical Audit performance and an Annual Report, while the National Cancer Control Programme reviews the guideline and oversees updates through the national approval process.[1][30]

• Monitor implementation and patient outcomes through audit criteria designed to assess effects on patient care.[30][32]
• Agree Key Performance Indicators through the Prostate National Clinical Lead's Network and hold annual multidisciplinary Cancer Quality and Audit Fora.[29]
• Review performance and service plans through quarterly meetings between the National Cancer Control Programme Cancer Network Manager and each cancer centre.[30]
• Conduct periodic literature surveillance and consider the guideline for review three years after its June 2015 publication; subject interim or full updates to National Clinical Effectiveness Committee approval and publish records on National Cancer Control Programme and National Clinical Effectiveness Committee websites.[30]
• Maintain evidence governance by updating searches before external review, checking cited evidence for retractions or withdrawals, retaining search records, and logging stakeholder-review amendments.[27][28][42]

Clinical monitoring is embedded in care pathways rather than limited to programme-level measures. Active surveillance includes prostate-specific antigen testing, digital rectal examination, repeat biopsy, Gleason grade, cancer volume, number of positive cores and magnetic resonance imaging findings; changes in these measures and patient preference can trigger conversion to radical treatment.[15][43][44]Biochemical recurrence is defined as at least two prostate-specific antigen readings of 0.2 micrograms per litre after radical prostatectomy, or a value 2 micrograms per litre above post-radiotherapy nadir.[45][46]Palliative-care needs are to be assessed continuously and at major clinical or social transition points.[25][26]

Pathology standards create auditable reporting controls, including site-specific biopsy reports, separate Gleason scores, cancer extent, prognostic factors, surgical margins and extraprostatic extension.[11][12][13]External quality assurance participation is required for pathologists reporting prostate biopsies, while surgical-margin and extraprostatic-extension location can support feedback and clinical, radiological and pathology audit.[12][47][48]

Explicit service standards include offering rapid-access prostate-clinic appointments within 20 working days, completing first surgical treatment within 30 working days of the decision to treat, issuing biopsy histology within 10 working days in 80% of cases, and treating new radical-therapy patients within 15 working days of readiness.[32]The document does not provide a complete national indicator set, outcome targets, routine surveillance registry or consolidated reporting timetable beyond these specified mechanisms.[29][30][32]

Costing & Financing

The guideline was commissioned and funded by the National Cancer Control Programme, but no overall implementation budget, funding gap, resource-mobilisation plan or quantified allocation is specified.[29][27]Many recommendations are considered cost neutral because they reflect existing standard practice; recommendations requiring change are assessed for resource implications, with additional resources sought through the Health Service Executive service-planning process where needed.[30]

• Consider resource implications and health-system impact when formulating recommendations and undertake budget-impact assessment supported by economic literature searches.[27][28]
• Plan for increased outpatient follow-up, repeat biopsy, magnetic resonance imaging, theatre access, pathology workload, equipment and staff training for active surveillance and transperineal biopsy.[43][44]
• Recognise that active-surveillance costs may be offset by savings from fewer radical treatments, although no relevant published economic evaluation or additional economic analysis was identified.[43]
• Use the Health Service Executive medicine-assessment and reimbursement process, informed by National Centre for Pharmacoeconomics assessment, National Cancer Control Programme priorities and company submissions, to support sustainable access to cancer medicines.[49][50]

Economic evidence uses a health-sector perspective for Irish appraisal and treats United Kingdom findings as broadly indicative where epidemiology, patient demographics and treatment pathways are similar.[51][52]Ireland has no explicit threshold for non-drug interventions, although ratios of Euro 20,000 to Euro 45,000 per quality-adjusted life year are conventionally considered cost-effective.[51][53]Magnetic resonance imaging staging was cost-effective in all modelled scenarios and dominant in most, but limitations in the underlying German and Austrian evidence prevent firm conclusions for Ireland.[53][54]

Active-surveillance costs are quantified at Euro 1,430.18 per patient over five years and Euro 1,161,306.10 annually for 812 prostate cancers diagnosed each year.[49]The pathway lists Year 4 costs of Euro 137.20 and Year 5 costs of Euro 373.26 per patient.[49]The source reports no budget impact from magnetic resonance imaging access for 812 men because imaging was already current practice.[49]

For bone-targeted treatment, zoledronic acid was considered likely to be the most cost-effective option, with an estimated market price below Euro 50 compared with a Health Service Executive high-tech reimbursed price of Euro 356.99 for denosumab.[55]Denosumab had been considered cost-effective against zoledronic acid in 2011, but subsequent price changes require formal re-appraisal.[55]Routine endorectal-coil and 3T magnetic resonance imaging, wider SPECT-CT availability and cyclotron upgrading would entail cost or substantial investment, but no values are provided.[34][56]

Historical context indicates that cancer cost the European Union Euro 126 billion in 2009, including Euro 51 billion in healthcare costs, while prostate cancer cost Euro 8.43 billion.[3]Irish cancer-related healthcare costs were estimated at Euro 619 million, including inpatient care, medicines, primary care, outpatient care and emergency care.[3]